Document is current
Any future updates will be listed below
-
Authors
Mosbah, H.
Donadille, B. https://orcid.org/0000-0002-5507-4782
Vatier, C.
Janmaat, S.
Atlan, M.
Badens, C.
Barat, P.
Béliard, S.
Beltrand, J.
Ben Yaou, R.
Bismuth, E.
Boccara, F.
Cariou, B.
Chaouat, M.
Charriot, G.
Christin-Maitre, S.
De Kerdanet, M.
Delemer, B.
Disse, E.
Dubois, N.
Eymard, B.
Fève, B.
Lascols, O.
Mathurin, P.
Nobécourt, E.
Poujol-Robert, A.
Prevost, G.
Richard, P.
Sellam, J.
Tauveron, I.
Treboz, D.
Vergès, B.
Vermot-Desroches, V.
Wahbi, K.
Jéru, I.
Vantyghem, M. C.
Vigouroux, C.
-
Funding
Funding for this research was provided by:
Assistance Publique - Hôpitaux de Paris; Sorbonne University
French Ministry of Solidarity and Health
- License Information
-
More Information
Article History
Received: 18 October 2021
Accepted: 24 March 2022
First Online: 19 April 2022
Declarations
:
: Not applicable.
: Not applicable.
: The National Diagnostic and Care Protocol (PNDS) for Dunnigan syndrome was developed in its first version by accredited reference and competence PRISIS centers, with methodological support from the French National Health Authority (HAS), in application of the provisions of the National Rare Diseases Plan 2005–2023. This new version is placed under the sole editorial responsibility of the PRISIS network.
: The authors declare that they have no competing interests related to the content of the present manuscript. All participants in the drafting of the PNDS have filled out a declaration of interest, all of which are available at endocrino-sat.aphp.fr/prisis. BD reports consulting fees/meeting fees from Sanofi and speaking fees from Novartis, Lilly, Sanofi. BV reports consulting fees/meeting fees from NovoNordisk, Astra-Zeneca. CVa reports consulting fees/meeting fees from MSD, NovoNordisk, Sanofi, Aegerion, AstraZeneca; and research funding from Sanofi. CVi reports consulting fees/meeting fees from Aegerion, Pierre Fabre Medicament, and speaking fees from NovoNordisk, Laboratoires Servier, Lilly, Ipsen Pharma, Aegerion Pharmaceuticals. EB reports consulting fees/meeting fees from Medtronic, Abbot, Lilly, Insulet; speaking fees from NovoNordisk, Lilly, Orkyn, Abbot, DinnoSanté and research funding from Lilly. GP reports consulting fees/meeting fees from Lilly, NovoNordisk, Sanofi, Abbot, Medtronic, MSD, Becton Dickinson. IT reports consulting fees/meeting fees from MSD, Pfizer SAS, Pharma Dom, Novartis, Astra Zeneca, Sanofi, Recordati Rare Disease. MA reports consulting fees/meeting fees from Allergan, Motiva, Sebbin and research funding from PHRC, Sebbin. PR reports research funding from Roche. SCM reports consulting fees/meeting fees from Ipsen and Ferring Pharmaceuticals. SB reports reports consulting fees/meeting fees from Akcea Therapeutics, Sanofi, Amgen, JESFC, Univadis, Lilly. APR; DT; EN; GC; HM; KW; MC; MCV; MDK; ND; RBY; SJ; VVD did not report any conflicts of interest.
